BCL2 and diffuse large B-cell lymphoma: M. R. Schnorenberg elucidated synergistic treatment in diffuse large B-cell lymphoma (DLBCL) by triggering apoptosis by reactivating the tumor protein p53 with the suture peptide ATSP-7041, and BH3 mimetic ABT-263 (navitoclax) was administered to enhance sensitivity to BCL-2 family.